• <menu id="888u4"><menu id="888u4"></menu></menu>
  • Improvement of Diagnostic and Vaccine Tools for Emerging and Re-emerging Animal Health Threats

    Closed for proposals

    Project Type

    Coordinated Research Project

    Project Code

    D32035

    CRP

    2254

    Approved Date

    24 December 2019

    Status

    Active - Ongoing

    Start Date

    13 March 2020

    Expected End Date

    31 December 2025

    Participating Countries

    Australia
    Austria
    Ethiopia
    Indonesia
    Kenya
    Pakistan

    Description

    Vaccination has proved to be the best preventive measure against infectious diseases. Despite all the successes there are a number of limitations to the currently practised approaches. In veterinary medicine the application of vaccines by injection limits their use?for small ruminants? in rural areas . This practice requires well trained staff taking care to keep utmost hygiene and maintain a cold chain for the vaccines. Additionally injected vaccines do rarely induce production of specific mucosal?antibodies (IgA)?covering the mucosal tissues in nose, mouth and lungs?which scavenge bacteria or viruses before they can enter the body.? Such IgA antibodies can efficiently be induces by "mucosal" vaccines, i.e. formulations which are applied to the nose, mouth or eyes. Such vaccines and specifically the eye drop vaccines have the big advantage that you need only small volumes, application can be done by village vaccinators and the cool chain will be much easier to maintain. Recent experiments formulating such mucosal vaccines for ruminants presented a number of challenges namely too?low viscosity leading to spills, unsuitable components for freeze drying or the process of formulating the components appropriately. Additionally the measurement of IgA is still done by a "research tool" and?existing general laboratory tools have to be adapted to allow their measurement in standard laboratories. ?
    The expected outcome of this CRP is the ?development of a number of different mucosal vaccine formulations?against viral diseases like PPR or influenza or against bacterial diseases like Mycoplasmas or Pasteurella. In parallel the tools to measure specific IgA induced in the mucosals ?will be developed and applied. Experimental combinations of live attenuated viruses together with killed bacterial preparations will be tested to evaluate an enhancing effect of such combinations.
    ?

    Objectives

    To develop protocols for the production and formulation of biologicals for mucosal application. This includes the development of serological and immunological tools to quantify the effects of different formulations

    Specific objectives

    Develop mucosal formulations and SOPs for attenuated viruses like PPR or irradiated viruses like Influenza to serve as immune inducers for other pathogens inactivated by irradiation or bacterins .

    Develop methods to measure mucosal immune response using isotope, fluorescent or enzyme-labelled antibodies

    Correlate mucosal immune response to protection and the cellular immune response elicited

    Evaluate the effect of irradiation on selected compounds to increase the efficiency and effectiveness of mucosal formulations

    Evaluate formulation components for mucosal applications towards technical feasibility (Freeze drying, stability of product...)

    Evaluate the cost benefits of mucosal vaccines

    Contact the project officer

    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Image CAPTCHA

    Stay in touch

    Newsletter

    午夜爱爱爱爱爽爽爽视频网站